HR+/HER2- breast cancer patients had the highest probability of PIK3CA mutation (46.7%), and HER2+ breast cancer patients had the lowest probability of PIK3CA mutation (29.0%), but the difference was not statistically significant compared with other subtypes of breast cancer patients (p > 0.05, Fig. 2). This evidence concerns the gene ERBB2 and breast cancer.